Compare · LGVN vs NVO
LGVN vs NVO
Side-by-side comparison of Longeveron Inc. (LGVN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LGVN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 7687.5x LGVN ($23.8M).
- Over the past year, LGVN is down 38.4% and NVO is down 44.9% - LGVN leads by 6.6 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 6 for LGVN).
- NVO has more recent analyst coverage (25 ratings vs 2 for LGVN).
- Company
- Longeveron Inc.
- Novo Nordisk A/S
- Price
- $0.76+4.33%
- $41.55+1.32%
- Market cap
- $23.8M
- $183.15B
- 1M return
- -13.17%
- -9.84%
- 1Y return
- -38.38%
- -44.94%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 6
- 8
- Recent ratings
- 2
- 25
Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LGVN
- Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
- Longeveron Inc. filed SEC Form 8-K: Leadership Update
- Longeveron to Present at BIO International Convention 2026
- SEC Form DEFA14A filed by Longeveron Inc.
- SEC Form DEF 14A filed by Longeveron Inc.
- Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
- SEC Form SCHEDULE 13G filed by Longeveron Inc.
- Longeveron Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
- SEC Form 10-Q filed by Longeveron Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care